Controlled nonviral gene delivery and expression using stable neural stem cell line transfected with a hypoxia‐inducible gene expression system

Abstract

We propose that NSCs engineered with the Epo-SV-therapeutic gene will be valuable for developing a controllable stem cell-mediated nonviral gene therapy for SCI or other central nervous system diseases accompanied with chronic or episodic hypoxic/ischemic stresses.